Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI

Next Previous
Search
Trial Profile

Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Acronyms NATHAN-NEVER

    • Most Recent Events

    • 28 Dec 2020 Results of meta-analysis comparing safety and efficacy of pP2Y12-I versus Clopidogrel in patients with CAD undergoing elective PCI published in the American Journal of Cardiology
    • 23 Mar 2017 Primary endpoint has been met. (Apoptosis rate in HUVEC) as per results published in the Thrombosis and Haemostasis
    • 23 Mar 2017 Results published in the Thrombosis and Haemostasis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top